{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:34Z","timestamp":1786982134866,"version":"build-2736575974"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T00:00:00Z","timestamp":1648252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T00:00:00Z","timestamp":1648252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s11912-022-01247-7","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T17:06:32Z","timestamp":1648487192000},"page":"917-927","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["The Treatment Landscape of Advanced Hepatocellular Carcinoma"],"prefix":"10.1007","volume":"24","author":[{"given":"Kit Man","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gentry G.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,26]]},"reference":[{"key":"1247_CR1","unstructured":"CANCER TODAY provides data visualization tools that present current national estimates of the incidence, mortality, and prevalence of 36 cancer types in 185 countries, by sex and age group. https:\/\/gco.iarc.fr\/today\/online-analysis-multibars?v=2020&mode=cancer&mode_population=countries&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=10&group_cancer=1&include_nmsc=0&include_nmsc_other=1&type_multiple=%257B%2522inc%2522%253Atrue%252C%2522mort%2522%253Afalse%252C%2522prev%2522%253Afalse%257D&orientation=horizontal&type_sort=0&type_nb_items=%257B%2522top%2522%253Atrue%252C%2522bottom%2522%253Afalse%257D. Accessed 20 Mar 2022."},{"issue":"2","key":"1247_CR2","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology. 2018;68(2):723\u201350. https:\/\/doi.org\/10.1002\/hep.29913.","journal-title":"Hepatology"},{"issue":"15","key":"1247_CR3","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1200\/jco.2015.64.7412","volume":"34","author":"JL Petrick","year":"2016","unstructured":"Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS. Future of Hepatocellular carcinoma incidence in the United States Forecast Through 2030. J Clin Oncol. 2016;34(15):1787\u201394. https:\/\/doi.org\/10.1200\/jco.2015.64.7412.","journal-title":"J Clin Oncol"},{"key":"1247_CR4","doi-asserted-by":"crossref","unstructured":"Crocenzi T, El-Khoueiry A, Yau T, et al. Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study. J Clin Oncol. 2018;36(suppl):abstr 4013.","DOI":"10.1200\/JCO.2017.35.15_suppl.4013"},{"issue":"4","key":"1247_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390. https:\/\/doi.org\/10.1056\/NEJMoa0708857.","journal-title":"N Engl J Med"},{"issue":"10126","key":"1247_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/s0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373. https:\/\/doi.org\/10.1016\/s0140-6736(18)30207-1.","journal-title":"Lancet"},{"key":"1247_CR7","doi-asserted-by":"crossref","unstructured":"Kudo M, Finn RS, Qin S, et al. A nalysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase\u00a0III study of lenvatinib (REFLECT). J Clin Oncol. 2019;37:suppl 4; abstr 186.","DOI":"10.1200\/JCO.2019.37.4_suppl.186"},{"issue":"10064","key":"1247_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/s0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56\u201366. https:\/\/doi.org\/10.1016\/s0140-6736(16)32453-9.","journal-title":"Lancet"},{"issue":"1","key":"1247_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jso.24086","volume":"113","author":"C Ang","year":"2016","unstructured":"Ang C, Miura JT, Gamblin TC, et al. Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options. J Surg Oncol. 2016;113(1):55\u201361. https:\/\/doi.org\/10.1002\/jso.24086.","journal-title":"J Surg Oncol"},{"issue":"6","key":"1247_CR10","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1172\/jci27236","volume":"116","author":"P Kaposi-Novak","year":"2006","unstructured":"Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest. 2006;116(6):1582\u201395. https:\/\/doi.org\/10.1172\/jci27236.","journal-title":"J Clin Invest"},{"issue":"2","key":"1247_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc3205","volume":"12","author":"E Gherardi","year":"2012","unstructured":"Gherardi E, Birchmeier W, Birchmeier C, Vande WG. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12(2):89\u2013103. https:\/\/doi.org\/10.1038\/nrc3205.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1247_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54\u201363. https:\/\/doi.org\/10.1056\/NEJMoa1717002.","journal-title":"N Engl J Med"},{"issue":"2","key":"1247_CR13","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/s1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282\u201396. https:\/\/doi.org\/10.1016\/s1470-2045(18)30937-9.","journal-title":"Lancet Oncol"},{"issue":"24","key":"1247_CR14","doi-asserted-by":"publisher","first-page":"6678","DOI":"10.1158\/1078-0432.ccr-13-1721","volume":"19","author":"TF Greten","year":"2013","unstructured":"Greten TF, Duffy AG, Korangy F. Hepatocellular carcinoma from an immunologic perspective. Clin Cancer Res. 2013;19(24):6678\u201385. https:\/\/doi.org\/10.1158\/1078-0432.ccr-13-1721.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1247_CR15","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1158\/1078-0432.ccr-06-2363","volume":"13","author":"N Kobayashi","year":"2007","unstructured":"Kobayashi N, Hiraoka N, Yamagami W, et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res. 2007;13(3):902\u201311. https:\/\/doi.org\/10.1158\/1078-0432.ccr-06-2363.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"1247_CR16","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1200\/jco.2006.09.4565","volume":"25","author":"Q Gao","year":"2007","unstructured":"Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25(18):2586\u201393. https:\/\/doi.org\/10.1200\/jco.2006.09.4565.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1247_CR17","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/hep.26731","volume":"59","author":"T Flecken","year":"2014","unstructured":"Flecken T, Schmidt N, Hild S, et al. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology. 2014;59(4):1415\u201326. https:\/\/doi.org\/10.1002\/hep.26731.","journal-title":"Hepatology"},{"issue":"4","key":"1247_CR18","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/ijc.25397","volume":"128","author":"F Shi","year":"2011","unstructured":"Shi F, Shi M, Zeng Z, et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer. 2011;128(4):887\u201396. https:\/\/doi.org\/10.1002\/ijc.25397.","journal-title":"Int J Cancer"},{"issue":"7593","key":"1247_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nature16969","volume":"531","author":"C Ma","year":"2016","unstructured":"Ma C, Kesarwala AH, Eggert T, et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature. 2016;531(7593):253\u20137. https:\/\/doi.org\/10.1038\/nature16969.","journal-title":"Nature"},{"issue":"3","key":"1247_CR20","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1158\/1078-0432.ccr-08-1608","volume":"15","author":"Q Gao","year":"2009","unstructured":"Gao Q, Wang XY, Qiu SJ, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009;15(3):971\u20139. https:\/\/doi.org\/10.1158\/1078-0432.ccr-08-1608.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1247_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1158\/2326-6066.cir-15-0110","volume":"4","author":"A Gabrielson","year":"2016","unstructured":"Gabrielson A, Wu Y, Wang H, et al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC. Cancer Immunol Res. 2016;4(5):419\u201330. https:\/\/doi.org\/10.1158\/2326-6066.cir-15-0110.","journal-title":"Cancer Immunol Res"},{"issue":"10088","key":"1247_CR22","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/s0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492\u2013502. https:\/\/doi.org\/10.1016\/s0140-6736(17)31046-2.","journal-title":"Lancet"},{"issue":"7","key":"1247_CR23","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/s1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940\u201352. https:\/\/doi.org\/10.1016\/s1470-2045(18)30351-6.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1247_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/jco.19.01307","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38(3):193\u2013202. https:\/\/doi.org\/10.1200\/jco.19.01307.","journal-title":"J Clin Oncol"},{"key":"1247_CR25","doi-asserted-by":"crossref","unstructured":"Yau T, Park JW, Finn RS, et al. CheckMate 459: a randomized, multi-center phase 3 study of nivolumab (NIVO) vs. sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma. Ann Oncol. 2019;30:(suppl 5): v851-v934.","DOI":"10.1093\/annonc\/mdz394.029"},{"key":"1247_CR26","doi-asserted-by":"crossref","unstructured":"Kudo M, Matilla A, Santoro A, et al. Checkmate-040: nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status. J Clin Oncol. 2019;37:suppl 4; abstr 327.","DOI":"10.1200\/JCO.2019.37.4_suppl.327"},{"key":"1247_CR27","doi-asserted-by":"crossref","unstructured":"Fessas P, Kaseb A, Wang Y, et al. Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. J Immunother Cancer.\u00a02020;8(2):e001033.\u00a0https:\/\/pubmed-ncbi-nlm-nih-gov.offcampus.lib.washington.edu\/32868393\/.","DOI":"10.1136\/jitc-2020-001033"},{"issue":"1","key":"1247_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012.","journal-title":"Immunity"},{"issue":"3","key":"1247_CR29","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1158\/1078-0432.ccr-18-1254","volume":"25","author":"MA Morse","year":"2019","unstructured":"Morse MA, Sun W, Kim R, et al. The role of angiogenesis in hepatocellular carcinoma. Clin Cancer Res. 2019;25(3):912\u201320. https:\/\/doi.org\/10.1158\/1078-0432.ccr-18-1254.","journal-title":"Clin Cancer Res"},{"key":"1247_CR30","doi-asserted-by":"publisher","first-page":"12624","DOI":"10.1038\/ncomms12624","volume":"7","author":"JJ Wallin","year":"2016","unstructured":"Wallin JJ, Bendell JC, Funke R, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016;7:12624. https:\/\/doi.org\/10.1038\/ncomms12624.","journal-title":"Nat Commun"},{"issue":"20","key":"1247_CR31","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1915745.","journal-title":"N Engl J Med"},{"key":"1247_CR32","doi-asserted-by":"crossref","unstructured":"Finn RS, Qin S, Ikeda M, al. e. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2021;39:suppl 3; abstr 267.","DOI":"10.1200\/JCO.2021.39.3_suppl.267"},{"key":"1247_CR33","doi-asserted-by":"crossref","unstructured":"Kelley RK, Yau T, Cheng AL, et al. Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): results from the randomized phase III COSMIC-312 trial. Ann Oncol. 2022; 2021; VP10\u20132021.","DOI":"10.1016\/j.annonc.2021.10.008"},{"issue":"26","key":"1247_CR34","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/jco.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960\u201370. https:\/\/doi.org\/10.1200\/jco.20.00808.","journal-title":"J Clin Oncol"},{"key":"1247_CR35","doi-asserted-by":"crossref","unstructured":"Ross S, Mullins S, Watkins A, et al. Preclinical modelling of immune checkpoint blockade (P2012). J Immunol. 2013;190:(1 Supplement) 214.7.","DOI":"10.4049\/jimmunol.190.Supp.214.7"},{"key":"1247_CR36","doi-asserted-by":"crossref","unstructured":"Kelley RK, Sangro B, Harris WP, et al. Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination withdurvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC). J Clin Oncol. 2020;38:suppl; abstr 4508.","DOI":"10.1200\/JCO.2020.38.15_suppl.4508"},{"key":"1247_CR37","doi-asserted-by":"crossref","unstructured":"McCoon P, Lee YS, Kelley RK, et al. T-cell receptor pharmacodynamics associated with survival and response totremelimumab (T) in combination with durvalumab (D) in patients (pts) withunresectable hepatocellular carcinoma (uHCC). J Clin Oncol. 2021;39:suppl 15; abstr 4087.","DOI":"10.1200\/JCO.2021.39.15_suppl.4087"},{"key":"1247_CR38","doi-asserted-by":"crossref","unstructured":"Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol. 2022;4(suppl;abstr 379).\u00a0https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2022.40.4_suppl.379.","DOI":"10.1200\/JCO.2022.40.4_suppl.379"},{"issue":"11","key":"1247_CR39","doi-asserted-by":"publisher","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","volume":"6","author":"T Yau","year":"2020","unstructured":"Yau T, Kang YK, Kim TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 2020;6(11):e204564. https:\/\/doi.org\/10.1001\/jamaoncol.2020.4564.","journal-title":"JAMA Oncol."},{"key":"1247_CR40","unstructured":"FDA. FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma.\u00a0https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-nivolumab-and-ipilimumab-combination-hepatocellular-carcinoma. Accessed 26 Sept 2021"},{"key":"1247_CR41","doi-asserted-by":"crossref","unstructured":"Yau T, Zagonel V, Santoro A, et al. Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advancedhepatocellular carcinoma (aHCC): Results from CheckMate 040. J Clin Oncol. 2020;38:suppl 4; abstr 478.","DOI":"10.1200\/JCO.2020.38.4_suppl.478"},{"issue":"36","key":"1247_CR42","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1200\/jco.20.02672","volume":"38","author":"JD Gordan","year":"2020","unstructured":"Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO GUIDELINE. J Clin Oncol. 2020;38(36):4317\u201345. https:\/\/doi.org\/10.1200\/jco.20.02672.","journal-title":"J Clin Oncol"},{"key":"1247_CR43","doi-asserted-by":"publisher","unstructured":"Wong JSL, Kwok GGW, Tang V, et al. Ipilimumab and nivolumab\/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. J Immunother Cancer. 2021;9(2)doi:https:\/\/doi.org\/10.1136\/jitc-2020-001945","DOI":"10.1136\/jitc-2020-001945"},{"key":"1247_CR44","doi-asserted-by":"crossref","unstructured":"Yau T, Lee JJX, Wong JSL, et al. Outcomes of tyrosine kinase inhibitors after immunotherapy in advanced hepatocellular carcinoma: a multi-center study. J Clin Oncol. 2021;39(suppl 15):suppl.e16181.","DOI":"10.1200\/JCO.2021.39.15_suppl.e16181"},{"issue":"suppl 15","key":"1247_CR45","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1200\/JCO.2021.39.15_suppl.4071","volume":"39","author":"M Ducreux","year":"2021","unstructured":"Ducreux M, Zhu AX, Cheng A-L, et al. IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor). J Clin Oncol. 2021;39(suppl 15):4071.","journal-title":"J Clin Oncol."},{"key":"1247_CR46","doi-asserted-by":"crossref","unstructured":"Zhu AX, Guan Y, Abbas AR, et al. Genomic correlates of clinical benefits from atezolizumab combined with bevacizumab vs. atezolizumab alone in patients with advanced hepatocellular carcinoma (HCC).\u00a0Cancer Res 2020;80(suppl 16;abstr nr CT044). https:\/\/www.researchgate.net\/publication\/345179794_Abstract_CT044_Genomic_correlates_of_clinical_benefits_from_atezolizumab_combined_with_bevacizumab_vs_atezolizumab_alone_in_patients_with_advanced_hepatocellular_carcinoma_HCC","DOI":"10.1158\/1538-7445.AM2020-CT044"},{"issue":"9","key":"1247_CR47","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","volume":"1","author":"SV Bratman","year":"2020","unstructured":"Bratman SV, Yang SYC, Iafolla MAJ, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nature Cancer. 2020;1(9):873\u201381. https:\/\/doi.org\/10.1038\/s43018-020-0096-5.","journal-title":"Nature Cancer."},{"issue":"suppl 15","key":"1247_CR48","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1200\/JCO.2020.38.15_suppl.3531","volume":"38","author":"C-H Hsu","year":"2020","unstructured":"Hsu C-H, Lu S, Abbas A, et al. Longitudinal and personalized detection of circulating tumor DNA (ctDNA) for monitoring efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2020;38(suppl 15):3531.","journal-title":"J Clin Oncol."},{"issue":"suppl 15","key":"1247_CR49","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1200\/JCO.2021.39.15_suppl.4103","volume":"39","author":"PM Kasi","year":"2021","unstructured":"Kasi PM, Budde G, Dayyani F, et al. Tumor-informed assessment of circulating tumor DNA and its incorporation into practice for patients with hepatobiliary cancers. J Clin Oncol. 2021;39(suppl 15):4103.","journal-title":"J Clin Oncol."},{"issue":"4","key":"1247_CR50","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/hep.25832","volume":"57","author":"S Roayaie","year":"2013","unstructured":"Roayaie S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer \u22642 cm: results from two Western centers. Hepatology. 2013;57(4):1426\u201335. https:\/\/doi.org\/10.1002\/hep.25832.","journal-title":"Hepatology"},{"key":"1247_CR51","doi-asserted-by":"crossref","unstructured":"Pinato DJ, Cortellini A, Pai M, et al. PRIME-HCC: Phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. J Clin Oncol. 2021;39:suppl 15; abstr e16131.","DOI":"10.1200\/JCO.2021.39.15_suppl.e16131"},{"key":"1247_CR52","doi-asserted-by":"crossref","unstructured":"Kaseb AO, Pestana RC, Vence LM, et al. Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plusipilimumab in patients with resectable HCC. J Clin Oncol. 2019;37:suppl 4; abstr 185.","DOI":"10.1200\/JCO.2019.37.4_suppl.185"},{"issue":"9","key":"1247_CR53","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1158\/2326-6066.cir-14-0069","volume":"2","author":"C Tang","year":"2014","unstructured":"Tang C, Wang X, Soh H, et al. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014;2(9):831\u20138. https:\/\/doi.org\/10.1158\/2326-6066.cir-14-0069.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"1247_CR54","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/jci67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687\u201395. https:\/\/doi.org\/10.1172\/jci67313.","journal-title":"J Clin Invest"},{"issue":"4","key":"1247_CR55","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1158\/2326-6066.cir-14-0196","volume":"3","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Nirschl CJ, Kochel CM, et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res. 2015;3(4):345\u201355. https:\/\/doi.org\/10.1158\/2326-6066.cir-14-0196.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"1247_CR56","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ng0396-241","volume":"12","author":"G Pilia","year":"1996","unstructured":"Pilia G, Hughes-Benzie RM, MacKenzie A, et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet. 1996;12(3):241\u20137. https:\/\/doi.org\/10.1038\/ng0396-241.","journal-title":"Nat Genet"},{"issue":"14","key":"1247_CR57","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1158\/0008-5472.can-04-4244","volume":"65","author":"MI Capurro","year":"2005","unstructured":"Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005;65(14):6245\u201354. https:\/\/doi.org\/10.1158\/0008-5472.can-04-4244.","journal-title":"Cancer Res"},{"issue":"4","key":"1247_CR58","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1499-3872(15)60396-4","volume":"14","author":"L Wang","year":"2015","unstructured":"Wang L, Yao M, Pan LH, Qian Q, Yao DF. Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2015;14(4):361\u20136.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"24","key":"1247_CR59","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000011130","volume":"97","author":"J Zhang","year":"2018","unstructured":"Zhang J, Zhang M, Ma H, et al. Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: an updated meta-analysis. Medicine (Baltimore). 2018;97(24): e11130. https:\/\/doi.org\/10.1097\/md.0000000000011130.","journal-title":"Medicine (Baltimore)"},{"issue":"24","key":"1247_CR60","doi-asserted-by":"publisher","first-page":"6418","DOI":"10.1158\/1078-0432.ccr-14-1170","volume":"20","author":"H Gao","year":"2014","unstructured":"Gao H, Li K, Tu H, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res. 2014;20(24):6418\u201328. https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-1170.","journal-title":"Clin Cancer Res"},{"key":"1247_CR61","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3389\/fimmu.2016.00690","volume":"7","author":"Z Jiang","year":"2016","unstructured":"Jiang Z, Jiang X, Chen S, et al. Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma. Front Immunol. 2016;7:690. https:\/\/doi.org\/10.3389\/fimmu.2016.00690.","journal-title":"Front Immunol"},{"issue":"15","key":"1247_CR62","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1158\/1078-0432.ccr-19-3259","volume":"26","author":"D Shi","year":"2020","unstructured":"Shi D, Shi Y, Kaseb AO, et al. Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials. Clin Cancer Res. 2020;26(15):3979\u201389. https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-3259.","journal-title":"Clin Cancer Res"},{"key":"1247_CR63","doi-asserted-by":"crossref","unstructured":"Zhao Z, Guo W, Fang S, et al. An armored GPC3-directed CAR-T for refractory or relapsed hepatocellularcarcinoma in China: a phase I trial. J Clin Oncol. 2021;39:suppl 15; abstr 4095.","DOI":"10.1200\/JCO.2021.39.15_suppl.4095"},{"key":"1247_CR64","doi-asserted-by":"crossref","unstructured":"Fang W, Fu Q, Zhao Q, et al. Phase I trial of fourth-generation chimeric antigen receptor T-cells targetingglypican-3 for advanced hepatocellular carcinoma. J Clin Oncol. 2021;39:suppl 15; abstr 4088.","DOI":"10.1200\/JCO.2021.39.15_suppl.4088"},{"issue":"suppl 1","key":"1247_CR65","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1016\/S0168-8278(20)30761-3","volume":"73","author":"B Sangro","year":"2020","unstructured":"Sangro B, Borad MJ, Hausner PF, et al. Data from the third dose cohort of an ongoing study with ADP-A2AFP SPEAR T-cells. J Hepatol. 2020;73(suppl 1):S122.","journal-title":"J Hepatol."}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01247-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-022-01247-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01247-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T09:09:00Z","timestamp":1675069740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-022-01247-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,26]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1247"],"URL":"https:\/\/doi.org\/10.1007\/s11912-022-01247-7","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,26]]},"assertion":[{"value":"10 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kit Man Wong has received institutional research funding from Genentech, Exelixis, Shanghai De Novo Pharmatech, Adaptimmune Therapeutics, Pfizer, Astellas, Replimune, Mitsubishi Tanabe Pharma, Eli Lilly, and AstraZeneca and has received compensation for participation on advisory boards from Genentech, Exelixis, and HalioDX. Gentry G. King has received institutional funding for clinical trials from Bayer; has received compensation for service as a consultant from Zymeworks and Tempus; has received compensation for participation on advisory boards from Pfizer and QED Therapeutics; has received speaker\u2019s honoraria from the Society for Immunotherapy of Cancer (SITC) and the International Society of Gastrointestinal Oncology (IGSIO); received reimbursement for travel\/accommodations from the IGSIO; is member of the National Cancer Institute (NCI) Hepatobiliary Task Force and Southwest Oncology Group; and is Co-Chair of the ctDNA GI Steering Committee. William P. Harris has received institutional research funding from Exelixis, Bristol-Myers Squibb, MedImmune, AstraZeneca, Bayer, Boston Scientific, Merck, Koo Foundation, and Zymeworks; has received compensation for service as a consultant from Zymeworks, Merck, and BD Medical; has received compensation for participation on advisory boards from Exelixis, AstraZeneca, and Eisai; and serves on the Board of Directors (unpaid) of the GI Cancers Alliance.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}